8 assets in Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)

Therapeutic assets addressing Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22), rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Etoposide Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)	Alice Mims	P3	BBB (75)
Azacitidine Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)	The First Affiliated Hospital of Soochow University	P2	BBB (73)
Cyclophosphamide Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)	Sumithira Vasu	P3	BB (69)
Gemtuzumab Ozogamicin Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)	Wake Forest University Health Sciences	P2	BB (64)
Avapritinib Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)	The First Affiliated Hospital of Soochow University	P1/2	CCC (48)